Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau)

World Journal of Urology

Volumn 33, Issue 8, 2015, Pages 1189-1196

  Randazzo, Marco ^a   Beatrice, Josef ^a   Huber, Andreas ^a   Grobholz, Rainer ^a   Manka, Lukas ^b   Wyler, Stephen F ^a   Chun, Felix F ^c   Recker, Franz ^a   Kwiatkowski, Maciej ^a  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b Academic Hospital Braunschweig   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Hypoglycemic agents; Metformin; Prostate cancer; Prostate specific antigen; Screening; Survival

Indexed keywords

ANTIDIABETIC AGENT; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; METFORMIN; PROSTATE SPECIFIC ANTIGEN;

AGED; BLOOD; CANCER GRADING; EARLY CANCER DIAGNOSIS; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; QUESTIONNAIRE;

AGED; EARLY DETECTION OF CANCER; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; KALLIKREINS; MALE; METFORMIN; MIDDLE AGED; NEOPLASM GRADING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVEYS AND QUESTIONNAIRES;

EID: 84938970298     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1426-y     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
2. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053
3. Hofner T, Zeier M, Hatiboglu G, Eisen C, Schonberg G, Hadaschik B, Teber D, Duensing S, Trumpp A, Hohenfellner M, Pahernik S (2013) The impact of type 2 diabetes on the outcome of localized renal cell carcinoma. World J Urol [Epub ahead pf print]
4. Zhang F, Yang Y, Skrip L, Hu D, Wang Y, Wong C, Qiu J, Lei H (2012) Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetol 49(Suppl 1):S235–S246
5. Oh JJ, Hong SK, Lee S, Sohn SJ, Lee SE (2013) Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy. Int Urol Nephrol 45:121–127
6. Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L (2014) Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25:329–338
7. Pollak M (2010) Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 3:1060–1065
8. Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A (2014) New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res 159:355–376
9. Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bartschi D, Pollak M, Lui L, Endt K, Schiess R et al (2014) Metformin in chemotherapy-naive castration-resistant prostate cancer: a Multicenter Phase 2 trial (SAKK 08/09). Eur Urol 66(3):468–474. doi:10.1016/j.eururo.2013.12.057
10. Demir U, Koehler A, Schneider R, Schweiger S, Klocker H (2014) Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells. BMC Cancer 14:52
11. Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20:1617–1622
12. Azoulay L, Dell’Aniello S, Gagnon B, Pollak M, Suissa S (2011) Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 20:337–344
13. Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N (2013) Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 105:1123–1131
14. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sørensen HT (2014) Metformin use and prostate cancer risk. Eur Urol. doi:10.1016/j.eururo.2014.04.027
15. Kwiatkowski M, Huber A, Stamm B, Lehmann K, Wernli M, Hafeli A, Recker F (2003) Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland. BJU Int 92(Suppl 2):44–47
16. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M et al (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981–990
17. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, et al (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet
18. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974
19. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N (2013) Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31:3069–3075
20. Zanders MM, Vissers PA, van de Poll-Franse LV (2014) Association between metformin use and mortality in patients with prostate cancer: Explained by confounding by indication?. J Clin Oncol
21. Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI, Herman M, Lotan Y, Seitz C, Schramek P, et al (2013) Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol
22. Vickers AJ, Lilja H (2012) PSA is dead, long live PSA. Eur Urol 61:467–468 discussion 469–470
23. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB (1995) Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274:1214–1220
24. Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R (2001) Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng/ml combined with free-to-total ratio 20% or less: the Aarau experience. J Urol 166:851–855
25. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA (2011) Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 128:635–643
26. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA (2009) Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 169:937–945
27. Muller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H (2009) Association of diabetes and body mass index with levels of prostate-specific antigen: Implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev 18:1350–1356
28. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR (2014) Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 311:2288–2296
29. Li CY, Sung FC (1999) A review of the healthy worker effect in occupational epidemiology. Occup Med (Lond) 49:225–229
30. Hadaegh F, Bozorgmanesh M, Safarkhani M, Khalili D, Azizi F (2011) Predictability of body mass index for diabetes: affected by the presence of metabolic syndrome? BMC Public Health 11:383